Survivin-3B promotes chemoresistance and immune escape by inhibiting caspase-8 and -6 in cancer cells
- PMID: 24353917
- PMCID: PMC3862639
- DOI: 10.4161/onci.26328
Survivin-3B promotes chemoresistance and immune escape by inhibiting caspase-8 and -6 in cancer cells
Abstract
Survivin-3B (S-3B), an alternative splice isoform of survivin, plays a key role in tumorigenesis. S-3B promotes the escape of malignant cells from immune recognition by blocking the cytotoxicity of natural killer (NK) cells. Such an effect reflects the ability of S-3B to interfere with the assembly of the so-called "death-inducing signaling complex" upon the interaction of FAS with its ligand (FASL). S-3B also inhibits the activation of caspase-6, thus increasing the resistance of neoplastic cells to granzyme B and various chemotherapeutics.
Keywords: caspase-6; caspase-8; survivin-3B; treatment response; tumor escape; tumorigenesis.
Figures

Similar articles
-
Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy.Cancer Res. 2013 Sep 1;73(17):5391-401. doi: 10.1158/0008-5472.CAN-13-0036. Epub 2013 Jul 15. Cancer Res. 2013. PMID: 23856250
-
[Implication of alternative splice transcripts of caspase-3 and survivin in chemoresistance].Bull Cancer. 2005 Mar;92(3):219-26. Bull Cancer. 2005. PMID: 15820916 Review. French.
-
Cleavage of survivin by Granzyme M triggers degradation of the survivin-X-linked inhibitor of apoptosis protein (XIAP) complex to free caspase activity leading to cytolysis of target tumor cells.J Biol Chem. 2010 Jun 11;285(24):18326-35. doi: 10.1074/jbc.M109.083170. Epub 2010 Apr 20. J Biol Chem. 2010. PMID: 20406824 Free PMC article.
-
Efficient recruitment of c-FLIPL to the death-inducing signaling complex leads to Fas resistance in natural killer-cell lymphoma.Cancer Sci. 2020 Mar;111(3):807-816. doi: 10.1111/cas.14296. Epub 2020 Jan 31. Cancer Sci. 2020. PMID: 31908105 Free PMC article.
-
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.Leuk Lymphoma. 1998 Nov;31(5-6):477-90. doi: 10.3109/10428199809057607. Leuk Lymphoma. 1998. PMID: 9922038 Review.
Cited by
-
Emerging Role of Circulating Tumor Cells in Gastric Cancer.Cancers (Basel). 2020 Mar 15;12(3):695. doi: 10.3390/cancers12030695. Cancers (Basel). 2020. PMID: 32183503 Free PMC article. Review.
-
Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'?Br J Cancer. 2022 Jul;127(2):173-184. doi: 10.1038/s41416-022-01768-9. Epub 2022 Mar 10. Br J Cancer. 2022. PMID: 35273384 Free PMC article. Review.
-
Aberrant Splicing as a Mechanism for Resistance to Cancer Therapies.Cancers (Basel). 2025 Apr 21;17(8):1381. doi: 10.3390/cancers17081381. Cancers (Basel). 2025. PMID: 40282556 Free PMC article. Review.
-
Alternative Splicing in Cancer and Immune Cells.Cancers (Basel). 2022 Mar 28;14(7):1726. doi: 10.3390/cancers14071726. Cancers (Basel). 2022. PMID: 35406498 Free PMC article. Review.
-
Survival Mechanisms and Influence Factors of Circulating Tumor Cells.Biomed Res Int. 2018 Nov 1;2018:6304701. doi: 10.1155/2018/6304701. eCollection 2018. Biomed Res Int. 2018. PMID: 30515411 Free PMC article. Review.
References
-
- Knauer SK, Bier C, Schlag P, Fritzmann J, Dietmaier W, Rödel F, Klein-Hitpass L, Kovács AF, Döring C, Hansmann ML, et al. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle. 2007;6:1502–9. doi: 10.4161/cc.6.12.4305. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous